Articles tagged with Liver Cancer
Researchers identified a new virus, AAV2, associated with rare liver cancer cases without cirrhosis or known risk factors. The virus targets genes involved in cell proliferation, leading to excessive expression and potentially favoring tumor development.
A University of Hawai'i Cancer Center researcher has received a $2.70 million grant to study how gut bacteria can damage the liver and promote liver cancer. The study aims to design new approaches to preventing liver cancer by regulating bile acid metabolism.
A new study published in Journal of Hepatology found that women with intrahepatic cholestasis of pregnancy (ICP) are at a higher risk of hepatobiliary cancer and immune-mediated diseases later in life. ICP affects nearly 0.4-1.5% of pregnancies and is characterized by itching, elevated serum bile acids, and/or liver enzymes.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have discovered a new way to improve liver cancer treatment by blocking the activity of the lymphotoxin-beta receptor. The approach, which combines drugs currently in clinical trials with those targeting oncogene signals, may lead to improved patient outcomes.
A large population-based study found that women with intrahepatic cholestasis of pregnancy (ICP) have a higher risk of hepatobiliary cancer, immune-mediated diseases, and cardiovascular disease compared to those without the condition. ICP is characterized by pruritus, elevated serum bile acids, and liver enzymes in late pregnancy.
New cancer cases are increasing globally, with significant rises in prostate and breast cancer since 1990. However, death rates from cancer are falling in many countries due to prevention and treatment progress.
Exposure to aflatoxin, a liver carcinogen, is associated with an increased risk of gallbladder cancer in a small Chilean study. The study found higher levels of aflatoxin-albumin adducts in patients with gallbladder cancer compared to controls.
Patients with liver cancer can be cured with a liver transplant using organs from donors who died of cardiac death, according to the largest study of its kind. The study found no difference in liver cancer recurrence between livers donated after cardiac death and those obtained from brain-dead donors.
A new class of protein-based contrast agents (PRCAs) has been developed to detect liver cancer at an early stage, providing robust results. The agent, ProCA32, allows for imaging of liver tumors measuring less than 0.25 millimeters with improved sensitivity and accuracy compared to existing methods.
Researchers discovered that cancer rates among hepatitis C patients are significantly higher than those without the virus. The study found a 2.5 times higher rate of all cancers and almost twice as high when liver cancer is excluded.
Researchers have discovered a damaged DNA lesion that may serve as an early biomarker for liver cancer. Polyphenon E, a green tea extract, also shows promise in suppressing the lesion and preventing tumor development.
Researchers have unraveled the relationships between microRNA miR-22, bile acids, and Cyclin A2 in liver and colon cancer. The study found that miR-22 reduces Cyclin A2 expression levels, potentially leading to new cancer therapies.
A new study published in the Journal of the American College of Surgeons found that liver-sparing operations, which remove less than a lobe of the liver, are linked to lower mortality and complication rates. This approach is associated with quicker recovery times and fewer complications compared to traditional major hepatectomies.
A new UK-based study reveals that statin users have a lower risk of developing liver cancer compared to non-users. The study found the association was strongest among current users and those with pre-existing conditions like diabetes or liver disease.
Scientists from RIKEN have found that chronic hepatitis infection and inflammation can lead to similar genetic mutations in liver tumors, potentially paving the way for targeted therapies. The study identified changes in mutations associated with aggressive biliary-type liver cancers and discovered new targets for future treatments.
Researchers have identified a critical safety parameter related to AAV gene therapy, which can increase liver cancer risk. They found that modifying the vector to avoid targeting specific genes reduces cancer incidence, paving the way for safer gene therapies.
Researchers from Ruhr-University Bochum found that terpenes in citrus scents can inhibit liver cancer cell growth. The study discovered the signalling pathway used by (-)-citronellal and citronellol, two terpenes with anti-cancer properties.
A novel nomogram was developed by UCLA researchers to accurately calculate the risk of disease recurrence in liver cancer patients after a liver transplant. The tool uses pre-transplant radiologic information, blood biomarkers, and pathological characteristics to predict recurrence rates.
Researchers have found a new potential target for liver cancer treatment in the protein TREM-1, which accelerates chronic inflammation. Studies suggest that blocking TREM-1 can block the conversion of healthy cells to cancerous ones and even stop progression of existing cancer.
A 30-year study found that neonatal HBV vaccination significantly reduced the risk of primary liver cancer and other liver diseases in young adults. The study's results show that vaccination led to a 84% reduction in liver cancer incidence, highlighting the importance of early intervention.
A new imaging system has shown potential to reduce radiation exposure for patients undergoing intra-arterial therapy (IAT) for liver cancer, with a reduction of up to 80%, compared to standard X-ray platforms. The AlluraClarity platform uses real-time image processing algorithms to achieve high-quality images at lower radiation power.
CPRIT awards UTSW faculty $22.5 million for groundbreaking research into leukemia, liver cancer, and anti-cancer immunotherapy, aiming to drive innovative therapies and better care for cancer patients. The grants will support investigations targeting promising new discoveries in cancer and commercial development.
Researchers will investigate how the Western diet increases the risk of developing liver and gastrointestinal cancers. They also aim to determine if specific bifidobacteria species can mitigate the negative effects of a high-fat, high-sugar diet.
Researchers at VCU Massey Cancer Center have identified a genetic driver of inflammation that can be used to prevent and treat liver cancer. The study found that blocking the expression of AEG-1 halts the development and progression of liver cancer by regulating inflammation.
A meta-analysis of 16 studies and 891,426 participants found that prediabetes increases the risk of cancer by 15%. The risk was higher for certain types of cancer, including stomach/colorectum, liver, pancreas, breast, and endometrium.
CRI scientists have identified a gene that contributes to the development of several childhood cancers, including neuroblastoma and hepatoblastoma. The study found that overproduction of Lin28b specifically causes hepatoblastoma, while blocking it impairs cancer growth.
Researchers predict that effective new drugs and widespread screening will reduce hepatitis C cases, prevent liver cancer and deaths. By 2036, the disease is expected to affect only one in 1,500 people in the US.
A study found that genetic mutations in liver cells drive tumor formation in iCCA, with mutant proteins impairing liver cell development and increasing the risk of metastasis. Researchers discovered a potential treatment option by targeting IDH1/2 mutations, opening a new line of investigation for biomarkers and life-saving decisions.
Two studies published in Gastroenterology found that antiviral therapy can reduce the risk of liver cancer in patients with chronic hepatitis B infection. Younger patients with minimal liver damage and those treated with nucleos(t)ide analogues showed a significant reduction in liver cancer risk.
The American College of Physicians recommends assessing a woman's health history for unique events that increase her risk of stroke later in life. For chronic hepatitis C patients, routine screening for liver cancer may not lead to greater survival.
Scientists have developed a liver cancer vaccine that is effective in preventing the disease in mice, with the goal of improving patient survival rates. The vaccine targets a specific protein expressed by most liver cancer cells, allowing the immune system to recognize and attack them.
A review of 47 studies involving over 15,000 patients found that liver cancer screening using ultrasound scans and blood tests significantly improved three-year survival rates for people with cirrhosis. Cirrhosis patients who received screening were more likely to receive curative treatment rather than palliative care.
Deaths from viral hepatitis have surpassed HIV/AIDS as a preventable cause of death in Australia, with an estimated 1,500 liver cancer deaths per year. Chronic viral hepatitis can lead to cirrhosis or liver cancer if left untreated, but access to effective care and treatment can reduce these risks.
Researchers have discovered an immunotherapeutic approach to treating liver cancer, utilizing isolated T-cell receptors that can recognize and eliminate liver cancer cells. This new treatment option holds promise for patients with limited treatment options, including those with advanced stage HCC.
A new study found that antioxidants may increase DNA damage from omega-6 fatty acids, but reduce formation of another type of damage. Green tea polyphenol and alpha-lipoic acid showed mixed effects on these damages.
A University of Colorado Cancer Center study identifies AGL as a key driver of bladder cancer growth, linked to hereditary liver disease glycogen storage disease 3. Low AGL levels correlate with poorer prognosis and increased tumor proliferation.
Researchers at Johns Hopkins Medicine have developed a new technology that uses 3D MRI scans to precisely measure living and dying tumor tissue, allowing for more accurate predictions of patient survival after chemotherapy. The technology has been shown to improve survival rates by up to 19 months in patients with liver tumors.
Researchers identified UHRF1 as a key driver of liver cancer in zebrafish models and human tumors, showing that high levels of UHRF1 can cause tumors to form rapidly. The study suggests that targeting UHRF1 could be an effective approach to halting cancer formation and offers new hope for treatments for hepatocellular carcinoma.
A study by University of Iowa researchers identifies CHOP as a protein that promotes liver cancer in mice, linked to cellular stress from obesity, alcoholism, and viral hepatitis. Elevated CHOP levels are found in human liver tumors, suggesting potential targets for therapies.
Researchers identified a molecular link between liver cancer, cellular stress and health problems that increase the risk of developing this cancer. The protein CHOP promotes liver cancer in mice and may do so in humans too.
Michigan State University researchers discovered a genetic deficiency in male mice that triggers the development of liver cancer and type 2 diabetes. The study found altered NCOA5 gene levels led to glucose intolerance and hepatocellular carcinoma.
A team of Singapore scientists has made a breakthrough in understanding the molecular basis of bile duct cancer by mapping human genes disrupted in cholangiocarcinoma. The study identified several genes that were repeatedly disrupted in CCA development, suggesting new potential avenues for treatment.
Researchers at NUS found that activating Rho protein suppresses liver malignancies, providing evidence for signalling crosstalk between proteins in regulating liver overgrowth and cancer. The study paves the way for developing targeted therapeutics for liver cancer.
Researchers identified a novel HBV mutation in Korean men that may explain the gender disparity in liver cancer incidence. The mutation is associated with severe liver disease and was found exclusively in male patients.
Cancer is the leading cause of death among Hispanic Texans under 76, with lower rates of breast and colon cancer screenings. Despite advanced cancer stages at diagnosis, Hispanics experience higher survival rates than non-Hispanic whites.
Researchers developed a test that can clearly distinguish early liver cancer cells from normal liver cells by giving them a distinctive red-brown hue. The test uses a probe to detect and stain a microRNA called mir-21, which is found in liver cancer but not healthy liver cells.
A team of Singaporean and Taiwanese scientists have discovered that Aristolochic Acid (AA), a natural compound found in traditional Asian herbal remedies, is the most potent carcinogen identified to date, causing extensive DNA mutations. The study also reveals AA's possible link to liver cancer and calls for increased public awareness ...
A cohort study published in JNCI found a statistically significant elevated standardized incidence ratio for primary liver cancer among workers exposed to trichloroethylene. However, no significant risk was observed for kidney cancer or non-Hodgkin lymphoma. The authors suggest that further research is needed to confirm these findings.
Researchers found a key role for chaperones in protein assembly and regulation of the proteasome's functionality. The study may reveal new targets for anticancer drugs and advance research on Parkinson's and Huntington's diseases.
A randomized trial found that home-based health education increased HBV screening rates and knowledge about the disease among Hmong Americans, overcoming cultural and language barriers. The study suggests using lay health workers to improve access to screenings and diagnoses.
Research suggests that monitoring hepatic function with HIDA SPECT prior to and during radiation therapy can help tailor treatment plans for unresectable liver cancer patients. This assessment method allows for personalized radiation doses while minimizing the risk of liver injury.
Researchers at Johns Hopkins Medicine developed a method to track liver tumors' response to chemotherapy using paired CT scans, allowing for immediate feedback on treatment effectiveness. This technique has the potential to save patients from delayed diagnosis and reduced treatment efficacy.
Researchers at UNC discovered that the hepatitis C virus binds with microRNA miR-122 to protect itself, promoting viral replication. This interaction presents a promising target for new drugs to treat the infection.
A parasitic worm, prevalent in Southeast Asia, is believed to cause infections that contribute to liver cancer. The grant-funded research aims to understand how the worm's granulin secretion enhances tumorigenic environments and may lead to the development of a treatment.
A study found that enzyme levels in routine blood tests are a better predictor of liver cancer risk than hepatitis infection or other factors. The research used data from over 428,000 people and predicted 91% of liver cancer cases.
Researchers at the University of Southampton will investigate manipulating natural killer cells to attack hepatocellular cancer (HCC) cells. The study aims to create a method for clinical trials using NK cells for immunotherapy, with potential for improving treatment outcomes for HCC patients.
Researchers have deciphered how a stress-inducible gene regulator, AP-1, controls the survival of liver tumor-initiating cells. Altering these proteins in mice impaired liver cancer development, providing new insights into liver cancer initiation.
A study published in Cancer Research identified a gene that disrupts the inflammatory process implicated in liver cancer. Laboratory mice bred without this gene lacked pro-inflammatory protein TREM-1 and protected themselves from developing liver cancer after exposure to carcinogens.
Researchers at Ohio State University found that liver cancer cells lose the ability to produce glucose due to microRNA-23a overexpression. Suppressing miR-23a might reverse this process and offer a new treatment for hepatocellular carcinoma, the most common form of liver cancer.
A new study published in the journal Stem Cell reveals an antibody developed by researchers can detect stem cells in organs like the liver and pancreas. This breakthrough helps understand tissue regeneration and cancer diagnosis and treatment.